{"id":2346,"date":"2024-05-01T14:59:23","date_gmt":"2024-05-01T14:59:23","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2346"},"modified":"2024-05-01T14:59:24","modified_gmt":"2024-05-01T14:59:24","slug":"pfizer-reports-strong-revenue-and-adjusts-profit-outlook-driven-by-cost-cuts-and-non-covid-sales","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/05\/01\/pfizer-reports-strong-revenue-and-adjusts-profit-outlook-driven-by-cost-cuts-and-non-covid-sales\/","title":{"rendered":"Pfizer Reports Strong Revenue and Adjusts Profit Outlook, Driven by Cost Cuts and Non-Covid Sales"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Pharmaceutical Giant&#8217;s Performance Signals Recovery Amid Decline in Covid Product Demand<\/h4>\n\n\n\n<p>Pfizer&#8217;s (PFE) first-quarter results surpassed expectations, with revenue beating forecasts and the company raising its full-year profit outlook. The pharmaceutical giant&#8217;s robust performance was fueled by its broad cost-cutting initiatives, a smaller-than-expected decline in Paxlovid sales, and strong demand for non-Covid products.<\/p>\n\n\n\n<p>The company now anticipates adjusted earnings of $2.15 to $2.35 per share for the fiscal year, up from its previous guidance. Pfizer remains confident in its business trajectory and cost reduction efforts, aiming to achieve at least $4 billion in savings by year-end.<\/p>\n\n\n\n<p>While grappling with the diminishing demand for its Covid products, Pfizer is refocusing on its non-Covid portfolio and bolstering its bottom line. Despite a significant drop in Covid-related revenue, the company&#8217;s non-Covid products experienced notable growth, particularly those from its recent acquisition of Seagen.<\/p>\n\n\n\n<p>Key drivers of revenue growth include the strong performance of Vyndaqel drugs, Eliquis, and pneumococcal pneumonia shots. However, Pfizer&#8217;s new vaccine for respiratory syncytial virus (RSV), Abrysvo, fell short of revenue expectations, highlighting ongoing challenges in product launches.<\/p>\n\n\n\n<p>Despite headwinds such as competitive pressures and price decreases in certain markets, Pfizer&#8217;s strategic focus on non-Covid products signals a resilient path forward as it navigates market dynamics and works toward sustained profitability.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/05\/01\/new-york-community-bancorp-charts-path-to-recovery-despite-first-quarter-losses\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">New York Community Bancorp Charts Path to Recovery Despite First Quarter Losses<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical Giant&#8217;s Performance Signals Recovery Amid Decline in Covid Product Demand Pfizer&#8217;s (PFE) first-quarter results surpassed expectations, with revenue beating forecasts and the company raising its full-year profit outlook. The pharmaceutical giant&#8217;s robust performance was fueled by its broad cost-cutting initiatives, a smaller-than-expected decline in Paxlovid sales, and strong demand for non-Covid products. The company [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1127,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[361,309],"tags":[420,421,429],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2346"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2346"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2346\/revisions"}],"predecessor-version":[{"id":2347,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2346\/revisions\/2347"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1127"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2346"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}